Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.32 |
| ▸ | PRKCB | P05771 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 2/20 | 0.30 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24424524 | 0.93 | FFAR4 (0.37) | FFAR4KDM5ATBK1 | |
| SCHEMBL29584891 | 0.93 | FFAR4 (0.37) | FFAR4KDM5ATBK1 | |
| SCHEMBL29586245 | 0.93 | FFAR4 (0.37) | FFAR4KDM5ATBK1 | |
| SCHEMBL24424523 | 0.93 | FFAR4 (0.37) | FFAR4KDM5ATBK1 | |
| SCHEMBL29585040 | 0.93 | FFAR4 (0.37) | FFAR4KDM5ATBK1 | |
| SCHEMBL24423911 | 0.93 | FFAR4 (0.37) | FFAR4KDM5ATBK1 | |
| SCHEMBL30298816 | 0.91 | KDM5A (0.31) | ACACBPRKCBFFAR4KDM5A | |
| SCHEMBL24423697 | 0.89 | TLR8 (0.33) | KDM5ATBK1 | |
| SCHEMBL24423698 | 0.89 | TLR8 (0.33) | KDM5ATBK1 | |
| SCHEMBL24423699 | 0.89 | TLR8 (0.33) | KDM5ATBK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606541-B2 | PPARg modulators and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-04-21 | — | — | US | disclosed |
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230062861-A1 | PPARg MODULATORS AND METHODS OF USE | PPARG, PPARA, PPARD | ACACB 386/4885PRKCB 327/4885FFAR4 25/4885 |
| US-12606541-B2 | PPARg modulators and methods of use | PPARG, PPARA, PPARD | ACACB 440/4885PRKCB 433/4885FFAR4 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.